ASH PREVIEW: Roche, Celgene, Gilead cancer drugs will grab headlines
This article was originally published in Scrip
Executive Summary
Roche, Celgene and Gilead Sciences cancer drugs are the focus for a number of doctors and investors at a big US medical meeting this weekend as new data will signal the commercial potential of the therapies in a growing blood disease market.